 RUTHERFORD, N.J., Jan. 28, 2021 GLOBE NEWSWIRE -- Cancer Genetics, Inc. the Company Nasdaq: CGIX, a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise approximately 10.0 million through the issuance of an aggregate 2,758,624 shares of its common stock or pre-funded warrants in lieu thereof and warrants to purchase up to an aggregate of 2,758,624 shares of common stock, at a combined purchase price of 3.625 per share of common stock or common stock equivalent in lieu thereof and associated warrant in a private placement priced at-the-market under Nasdaq rules. The closing of the private placement is expected to occur on or about February 1, 2021, subject to the satisfaction of customary closing conditions. 